Skip to main content

Cancer Genetics Files $100M Shelf Registration

NEW YORK (GenomeWeb) – Cancer Genetics on Thursday filed a shelf registration to offer up to $100 million in securities.

In its registration statement filed with the US Securities and Exchange Commission, the firm said that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units totaling up to $100 million in aggregate.

Net proceeds are intended for working capital and other general corporate purposes.

Cancer Genetics recently reported a 15 percent rise in revenues for its first quarter. The company said that it had cash and cash equivalents of $9.7 million at the end of Q1.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.